| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
7-Hydroxycoumarinyl-γ-linolenate targets cytosolic phospholipase A2 (cPLA2), an enzyme that hydrolyzes phospholipids at the sn-2 position to release arachidonic acid and other fatty acids. As a fluorogenic substrate, the compound is cleaved by cPLA2, releasing the fluorescent 7-hydroxycoumarin (umbelliferone) moiety. The increase in fluorescence is proportional to cPLA2 activity. This allows for the detection and quantification of cPLA2 enzymatic activity in vitro.
|
|---|---|
| ln Vitro |
Advice (This is our suggested protocol, which should be adjusted to suit your particular circumstances as it simply offers guidance). Calculating the activity of cPLA2α: 1. Sonicate 200μL of a high-affinity mixed micellar solution buffer (pH=7.2) containing 1,2-O-tetradecyl-sn-glycerol-3-phosphocholine (DTPC), Triton X-100, 0.3mM EDTA, 1μmCaCl2, and 300mM KCl. 2. Track the hydrolysis of 7-hydroxycoumarinyl-γ-linolenate continuously using a 360 nm excitation wavelength and a 460 nm emission wavelength. 3. Observe the 7-hydroxycoumarin synthesis by fluorescence spectroscopy.
In vitro, 7-Hydroxycoumarinyl-γ-linolenate is used as a fluorogenic substrate to monitor the enzymatic activity of cPLA2. The compound is cleaved by cPLA2, releasing the fluorescent 7-hydroxycoumarin (umbelliferone) moiety. The increase in fluorescence is measured to quantify cPLA2 activity. The substrate can be used in enzyme assays to study cPLA2 kinetics, inhibition, and regulation. The compound's fluorescence properties make it suitable for high-throughput screening of cPLA2 inhibitors. |
| ln Vivo |
Specific in vivo activity data for 7-Hydroxycoumarinyl-γ-linolenate are not detailed in the available literature. The compound is primarily used as a research tool for in vitro enzyme assays to study cPLA2 activity. Its potential in vivo applications would be limited to ex vivo analysis of cPLA2 activity in tissue samples. The compound is not used as a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme assays for 7-Hydroxycoumarinyl-γ-linolenate typically involve incubating the substrate with cPLA2 enzyme in an appropriate buffer. The compound is dissolved in DMSO and diluted in assay buffer to working concentrations. The reaction is initiated by adding the enzyme, and fluorescence is measured over time using a fluorescence plate reader with excitation at approximately 320-360 nm and emission at approximately 450-460 nm (typical for umbelliferone). The increase in fluorescence is proportional to cPLA2 activity. The assay can be used to determine enzyme kinetics or to screen for inhibitors.
|
| Cell Assay |
In vitro cell-based assays using 7-Hydroxycoumarinyl-γ-linolenate are performed to measure cPLA2 activity in cell lysates or intact cells. Cells are lysed and the lysate is incubated with the fluorogenic substrate. Fluorescence is measured to quantify cPLA2 activity. The compound can also be used to study the effects of drugs or genetic manipulations on cPLA2 activity in cells. The substrate is typically dissolved in DMSO and diluted in assay buffer or cell culture medium. Cell viability should be assessed to ensure the compound is not toxic at the concentrations used.
|
| Animal Protocol |
Specific in vivo animal experiment protocols for 7-Hydroxycoumarinyl-γ-linolenate are not detailed in the available literature. The compound is primarily used as a research tool for in vitro enzyme assays. For potential in vivo studies, the compound could be administered to animals to study cPLA2 activity in tissues, but such applications are not standard. The compound's use in vivo would require formulation for administration and validation of the fluorescence signal in tissue samples.
|
| ADME/Pharmacokinetics |
7-Hydroxycoumarinyl-γ-linolenate has a molecular weight of 422.56 g/mol and the formula C27H34O4. The compound is a synthetic fluorogenic substrate belonging to the coumarin ester class. It is an ester of 7-hydroxycoumarin (umbelliferone) and gamma-linolenic acid (GLA). For storage, the compound is kept at -20°C, protected from light. It is soluble in DMSO and other organic solvents. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for 7-Hydroxycoumarinyl-γ-linolenate are not provided in the available sources. As a research chemical, it is intended for laboratory use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves and eye protection. The compound may cause irritation to skin, eyes, and respiratory tract upon contact.
|
| References | |
| Additional Infomation |
7-Hydroxycoumarinyl-γ-linolenic acid ester is a coumarin compound and also an octadecane compound.
7-Hydroxycoumarinyl-γ-linolenate (CAS 161180-12-7) is a fluorescent substrate for cytosolic phospholipase A2 (cPLA2). It has the molecular formula C27H34O4 and a molecular weight of 422.56 g/mol. The compound is a synthetic fluorogenic substrate belonging to the coumarin ester class, specifically an ester of 7-hydroxycoumarin (umbelliferone) and the omega-6 fatty acid gamma-linolenic acid (GLA). 7-Hydroxycoumarinyl-γ-linolenate may be utilized to detect the enzymatic activity of cPLA2. It is intended for research use only. |
| Molecular Formula |
C27H34O4
|
|---|---|
| Molecular Weight |
422.556
|
| Exact Mass |
422.245
|
| CAS # |
161180-12-7
|
| PubChem CID |
91746434
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
563.5±50.0 °C at 760 mmHg
|
| Flash Point |
279.3±28.5 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.540
|
| LogP |
7.58
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
31
|
| Complexity |
644
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC1=CC2=C(C=C1)C=CC(=O)O2
|
| InChi Key |
LPIXSKJJCANUQD-QNEBEIHSSA-N
|
| InChi Code |
InChI=1S/C27H34O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-26(28)30-24-20-18-23-19-21-27(29)31-25(23)22-24/h6-7,9-10,12-13,18-22H,2-5,8,11,14-17H2,1H3/b7-6-,10-9-,13-12-
|
| Chemical Name |
(2-oxochromen-7-yl) (6Z,9Z,12Z)-octadeca-6,9,12-trienoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3665 mL | 11.8326 mL | 23.6653 mL | |
| 5 mM | 0.4733 mL | 2.3665 mL | 4.7331 mL | |
| 10 mM | 0.2367 mL | 1.1833 mL | 2.3665 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
